EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitQuerschnittstudieOpen Access · CC BY-NC-ND 4.0

Placebo design, reporting compliance, and methodological problems in randomized, placebo-controlled trials of Chinese herbal medicine: A cross-sectional study

Jingyi Yu, Sai Jiang, Yanan Wang, Hejing Pan, Hui Liu, Xuanlin Li, Yaolong Chen, Chengping Wen

Pharmacological Research · 2026-07 · 229 · 108244

DOI: 10.1016/j.phrs.2026.108244 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026-07. Verfasst von Jingyi Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), China. Electronic address: 1…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Randomized Controlled Trials as Topic, Research Design. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This cross-sectional study aimed to characterize the design, application, and reporting standards of Chinese herbal medicine placebos (CHM-placebos) in randomized controlled trials (RCTs) published between 2018 and 2025. METHODS: We searched the Web of Science database for RCTs involving Chinese herbal medicine (CHM) and matching placebos published from January 2018 to September 2025. Methodological quality was assessed using Risk of Bias Instrument for Use in Systematic reviews for Randomized Controlled trials (ROBUST-RCT). Reporting compliance was evaluated according to the Consolidated Standards of Reporting Trials (CONSORT) Extension for Chinese Herbal Medicine Formulas (CONSORT-CHM). Descriptive statistics summarized features of CHM-placebos' design. RESULT: A total of 136 trials were included. Methodological assessment revealed that "Allocation concealment" had the highest risk (definitely high risk: 4%, probably high risk: 19%). Reporting compliance with CONSORT-CHM placebo-specific items was low, only 16 trials (11.76%) fully reported the name and amount of each ingredient, 6 trials (4.41%) trials reported quality control and safety assessments, and 9 trials (6.62%) provided complete production information. Manufacturers' information was reported in 90 trials (66.18%). 33 trials (24.26%) reported that their CHM-placebos contained traditional Chinese medicine ingredients, with two trials using placebos composed entirely of TCM. CONCLUSION: Deficiencies persist in the CHM-placebos' design and reporting, especially regarding compositional transparency and quality verification. The use of CHM-placebos containing TCM ingredients challenges the fundamental principle of pharmacological inertness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalRandomized Controlled Trials as TopicResearch DesignCross-Sectional StudiesHumansPlacebosQuality Control

Stichwörter der Autor:innen

CONSORT-CHM statementChinese herbal medicinePlaceboRandomized controlled trialReporting qualityTraditional Chinese medicine

Substanzen

Drugs, Chinese HerbalPlacebos

Autor:innen und Institutionen

  • The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), China. Electronic address: 18968330072@163.com.
  • College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: js1825889472@163.com.
  • College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: 17596521593@163.com.
  • College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: phj221@163.com.
  • Research Unit of Evidence-Based Evaluation and Guidelines, Chinese Academy of Medical Sciences(2021RUO17), School of Basic Medical Sciences, Lanzhou University, Lanzhou, China. Electronic address: sxyafxlh@163.com.
  • College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China. Electronic address: lixuanlinhnzy@163.com.

Zitieren

APA

Yu, J., Jiang, S., Wang, Y., Pan, H., Liu, H., Li, X., Chen, Y., & Wen, C. (2026). Placebo design, reporting compliance, and methodological problems in randomized, placebo-controlled trials of Chinese herbal medicine: A cross-sectional study. Pharmacological Research, 229, 108244. https://doi.org/10.1016/j.phrs.2026.108244

Vancouver

Yu J, Jiang S, Wang Y, Pan H, Liu H, Li X, et al. Placebo design, reporting compliance, and methodological problems in randomized, placebo-controlled trials of Chinese herbal medicine: A cross-sectional study. Pharmacological Research. 2026;229:108244. doi:10.1016/j.phrs.2026.108244

BibTeX
@article{Yu2026,
  author = {Yu, Jingyi and Jiang, Sai and Wang, Yanan and Pan, Hejing and Liu, Hui and Li, Xuanlin and Chen, Yaolong and Wen, Chengping},
  title = {Placebo design, reporting compliance, and methodological problems in randomized, placebo-controlled trials of Chinese herbal medicine: A cross-sectional study},
  journal = {Pharmacological Research},
  year = {2026},
  volume = {229},
  pages = {108244},
  doi = {10.1016/j.phrs.2026.108244}
}
Kostenlos starten →